FOLR1 and acute myeloid leukemia: To target this refractory AML, we developed a FOLR1-specific CAR T-cell product (FH FOLR1-CART) using the single-chain variable fragment (scFv) of farletuzumab, CD28 transmembrane, 4-1BB costimulatory domain, and CD3ζ cytotoxicity domain (19).